Buzz Stocks: Juno Therapeutics Inc, Eli Lilly and Co, and Biogen Inc

Today's stocks to watch in the news include Juno Therapeutics Inc (JUNO), Eli Lilly and Co (LLY), and Biogen Inc (BIIB)

Nov 23, 2016 at 9:56 AM
facebook twitter linkedin

U.S. stocks are cautiously lower after closing at record highs last night. Among specific equities in focus today are biotech stocks Juno Therapeutics Inc (NASDAQ:JUNO), Eli Lilly and Co (NYSE:LLY), and Biogen Inc (NASDAQ:BIIB). Here's a quick look at what's driving JUNO, LLY, and BIIB.

  • After being halted in pre-market trading, JUNO is trading 33% lower at $19.95, and now resides on the short-sale restricted (SSR) list, after two patients in its leukemia drug trial died. The company is currently working with U.S. agencies to decide whether trials of JCAR015 will continue. JUNO shares have dropped more than 55% since their June highs, and touched a new all-time low of $19.40 out of the gate today. Even though JUNO is on the SSR list, over 19% of Juno Therapeutics Inc's float is already sold short -- an amount that would take two weeks of trading to cover, at the equity's average daily volume.
  • LLY is down 14.4 % at $65.03, and on the SSR list, after its Alzheimer's drug failed a late-stage trial. J.P. Morgan Securities cut its price target to $85 from $95 after the drug trial news. LLY shares are now down 22.8% in 2016, and plummeted to a new two-year low of $64.18 at the opening bell today. In the option pits, Eli Lilly and Co's Schaeffer's put/call open interest ratio (SOIR) of 0.35 sits at an annual low, indicating near-term option players haven't been more call-skewed in the past 12 months.
  • BIIB -- which also has an Alzheimer's drug in the works -- is down after LLY's disappointing drug news, giving up 6% to trade at $299.91. Today's move puts Biogen Inc shares 2.3% below year-to-date breakeven, and back beneath their 20-month moving average -- a trendline that has stifled rally attempts over the past year. Option buyers have been betting on more downside, with BIIB's 10-day put/call volume ratio at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) of 1.03 sitting higher than 88% of all other readings from the past year.

Stay on top of overnight news & big morning movers. Sign up now for Schaeffer's Opening View.


Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

Best stocks for October and worst stocks for October


Special Offers from Schaeffer's Trading Partners